{
  "doi": "10.1007/s10557-014-6542-9",
  "full_text": "CardiovascDrugsTher(2014)28:459\u2013468\nDOI10.1007/s10557-014-6542-9\nORIGINALARTICLE\nExtreme Urinary Betaine Losses in Type 2 Diabetes\nCombined with Bezafibrate Treatment are Associated\nwith Losses of Dimethylglycine and Choline but not\nwith Increased Losses of Other Osmolytes\nMichaelLever&ChristopherJ.McEntyre&PeterM.George&SandySlow&\nJaneL.Elmslie&HelenLunt&StephenT.Chambers&AmberParry-Strong&\nJeremyD.Krebs\nPublishedonline:25July2014\n#SpringerScience+BusinessMediaNewYork2014\nAbstract dimethylglycine excretion was higher (9-fold, p<0.001). Ex-\nPurpose Betainedeficiencyisaprobablecardiovascularrisk cretionsofcholine,andoftheosmolytesmyo-inositol,taurine\nfactorandacauseofelevatedhomocysteine.Urinarybetaine andglycerophosphorylcholine,werenotsignificantlydifferent\nexcretion is increased by fibrate treatment, and is also often betweengroups.Someparticipantsexcretedmorebetainethan\nelevated in diabetes. Does fibrate further increase betaine usualdietaryintakes.Severalbetainefractionalclearanceswere\nexcretionindiabetes,anddoesitaffecttheplasmaconcentra- >100 %. Betaine excretion correlated with excretions of the\ntions and excretions of related metabolites and of other osmolytesmyo-inositolandglycerophosphorylcholine,andal-\nosmolytes? sowiththeexcretionofcholineandN,N-dimethylglycine,butit\nMethods Samples from a previous study of type 2 diabetes wasinconclusivewhethertheserelationshipswereaffectedby\nwereselectedifparticipantsweretakingbezafibrate (n=32). bezafibratetherapy.\nThesesampleswerecomparedwithparticipantsmatchedfor Conclusions Increased urinary betaine excretions in type 2\nageandgenderandnotonafibrate(comparatorgroup,n=64). diabetesarefurtherincreasedbyfibratetreatment,sometimes\nBetaine,relatedmetabolites,andosmolytesweremeasuredin tomorethantheirdietaryintake.Concurrentbetainesupple-\nplasmaandurinesamplesfromthese96participants. mentationmaybebeneficial.\nResults Median urinary betaine excretion in those on\nbezafibrate was 5-fold higher than in the comparator group Keywords Diabetes .Fibrates .Betaineexcretion .\n(p<0.001),itself3.5-foldhigherthanthemedianreportedfor myo-inositol .Homocysteine .Osmolytes\nhealthy populations. In the bezafibrate group, median\n: : : :\nM.Lever(*) C.J.McEntyre P.M.George S.Slow Introduction\nJ.L.Elmslie\nBiochemistryUnit,CanterburyHealthLaboratories,P.O.Box151, Betaineanditsmetabolitesinbloodandurinearemarkersof\nChristchurch8140,NewZealand\ncardiovascular risk [1, 2], especially in diabetes, possibly\ne-mail:michael.lever@otago.ac.nz\nbecausebetainedeficiencyisacardiovascularriskfactor[3].\n:\nA.Parry-Strong J.D.Krebs Mostpatientstreatedwithbezafibratetolowerbloodtriacyl-\nDepartmentofMedicine,UniversityofOtagoWellington, glycerol excrete excessive urinary betaine (often >300 mg/\nWellington,NewZealand\nday)[4].Also,about30%ofpatientswithdiabeteshavean\nabnormallyhighurinarybetaineexcretion [3],andthislatter\nH.Lunt\nDepartmentofMedicine,UniversityofOtagoChristchurch, findinghasbeenrecentlyconfirmedinalargerpopulation[5].\nChristchurch,NewZealand Betaine deficiency disturbs one-carbon metabolism, and for\nexampleisassociatedwithanelevatedplasmahomocysteine\nS.T.Chambers\n[6\u20138],whichcanthereforebeamarkerofbetainedeficiency.\nPathologyDepartment,UniversityofOtagoChristchurch,\nChristchurch,NewZealand Itisnotclearhowfrequentlyelevatedplasmahomocysteineis\n460 CardiovascDrugsTher(2014)28:459\u2013468\ntheresultofbetainedeficiency,butifitiscommonthiscould osmolytes.Iftheeffectispredominantlyonbetaine,thiscould\nexplainsomeofthenegativeresultsofloweringhomocysteine be expected to attenuate the cardiovascular benefits from\nbytreatmentwithB-vitamins,sinceB-vitamintreatmentwill fibrates and therefore raise the possibility that concurrent\nnotcorrectabetainedeficiency. dietary betaine supplementation would be synergistic with\nSince betaine is an osmolyte, its deficiency compromises fibrate treatment, and justify further studies to evaluate the\ncell volume regulation, yet we have previously found that benefitofthistherapeuticcombination.\nelevationsinbetaineexcretionandelevationsintheexcretion A number of recent reports have associated the betaine\noftherenalosmolytesorbitolcorrelatepositivelyindiabetes analog, trimethylamine-N-oxide(TMAO), with cardiovascu-\n[9]. It is not uncommon and sometimes recommended to lar events [22\u201325]. Elevated plasma TMAO has been previ-\nprescribe fibrate drugs for treating severe hypertriglyc- ouslyassociatedwithrenalfailure[26,27].Thereforewealso\neridemia in diabetes [10\u201313], with increasing numbers of measured this component of plasma and urine to assess\nprescriptions in North America [14], and one question is whether it also is elevated in participants receiving fibrate\nwhether the already-elevated betaine excretion is further in- therapy. Because fibrate therapy, and changes in betaine, its\ncreased by this treatment. We have shown that, in healthy metabolite N,N-dimethylglycine [28] and TMAO, have all\nvolunteers,treatmentwithfenofibrateincreasesbetaineexcre- beenassociatedwithabnormalrenalfunction,acardiovascu-\ntionand thatthe larger the baselineexcretion of betaine, the larriskfactor,wealsoexaminedtherelationshipofosmolytes\nlargertheincreaseonfenofibratetreatment[15].Thusitcould andone-carbonmetaboliteswithmarkersofrenalfunctionin\nbe anticipated that in diabetes, when baseline betaine excre- thisstudy.\ntion is often greatly elevated, fibrate treatment could lead to\nverylargelossesofbetaine.Inviewofourobservationwith\nsorbitol,anotherimportantquestioniswhethertherewouldbe\nalso significant losses of other osmolytes or of other one- Methods\ncarbon metabolites. Additionally, we would like to know\nwhether the diabetes and fibrate induced urinary losses of Participants,SampleCollectionandSelection\nbetaine share a mechanism, and whether the mechanism or oftheComparatorGroup\nmechanisms are related to one-carbon metabolism or to os-\nmoregulation. The specimens collected during the DEWL SamplesfromtheDEWLstudywerearchivedat>\u221280C,then\n(DiabetesExcessWeightLoss)study[16]providedanoppor- used for the current study. The DEWL study compared pre-\ntunitytoilluminatesomeofthesequestions:theDEWLcohort scriptionsofhypocalorichighproteinandhighcarbohydrate\nwasagroupofoverweightandobeseparticipantswithtype2 dietsinoverweightandobese(BMI>27kg/m2)subjectswith\ndiabetes,32ofwhomwerebeingtreatedwithbezafibrate. type 2 diabetes, aged 30\u201375 years [16]. Exclusion criteria\nElevatedbloodlipidisastrongriskfactorforcardiovascu- were current weight-reducing medications, a weight loss of\nlardisease.Statinsareeffectiveandextensivelyuseddrugsfor >5%inthepast3months,orapsychiatricoreatingdisorder.\nlowering blood lipids, but 65\u201375 % of the cardiovascular Participantswerealsoexcludediftheirglycatedhaemoglobin\ndiseaseriskpersistsafterstatintherapy[17\u201319].Fibrateshave (HbA ) was >9.5 % (80 mmol/mol) or they had had renal\n1c\nbeen promoted as an adjunct therapy, especially in disease (estimated glomerular filtration rate <60 ml/min or\nhypertriglyceridaemia, which is common in type 2 diabetes urinealbumin:creatinineratio>30mg/mmolbasedona24-h\n[12, 13]; however, they can cause apparently unfavourable urine collection), abnormal liver enzymes, heart failure,\nchangesinrenalfunctionmarkerssuchasplasmacreatinine, known active malignancy or myocardial infarction in\nurea and homocysteine, although these are reversible and the preceding 6 months. A total of 419 participants\nthere are no changes in the glomerular filtration rate [20]. were recruited, but urine samples were only available\nThere is no compelling evidence to suggest that fibrates on 312 of these. The original DEWL study compared\nreducecardiovascularmortality, though atleast one member plasma and urine collected at four time points (0, 6, 12\nofthistherapeuticfamilyhasabeneficialeffectonmicrovas- and 24 months). No significant differences or even\ncular outcomes in type 2 diabetes and recently it has been trends (p<0.2) in the analytes measured in the present\nconfirmedthatfibratesreduceriskinthesub-populationwith study were observed between the diet prescriptions. The\natherogenicdyslipidaemia[21];however,thisisalsoapopu- study group included 32 participants being treated with\nlationthatislikelytobebetainedeficient[3,7].Itispossible bezafibrate. To investigate the effect of the fibrate, we\nthat the effect of fibrates on betaine, and consequentially compared these participants with an age (\u00b12 years) and\nhomocysteine,metabolismcontributestothelackofuniform- gender matched comparator group who were not taking\nlypositiveoutcomesoffibratetrials.Weaskedwhetherfibrate fibrates (n=64). This comparator group was randomly\ntherapy also affects the plasma concentrations and urinary selected from the same DEWL study cohort as the\nexcretions of betaine-related metabolites, and of other fibrate taking group.\nCardiovascDrugsTher(2014)28:459\u2013468 461\nReagentsandChemicals myo-Inositol was separated using anAgilent 1,200 Series\nHPLC system with an amide UPLC column, and detected\nGlycine betaine hydrochloride, N,N-dimethylglycine hydro- usinganAgilent6,120singlequadrupolemassspectrometer\nchloride,cholineiodide,glycerophosphorylcholine(cadmium with atmospheric pressure chemical ionization (APCI). An\nchloridecomplex),trimethylamine-N-oxide,taurine,carnitine isocratic system was used with a mobile phase containing\nhydrochloride,andacetylcarnitinehydrochloridewereobtain- 85 % acetonitrile and 15 % distilled water. The flow rate\ned from Sigma (St Louis, MO, USA). N,N,N-Trimethyl-D - was 0.3 mL/min, the injection volume was 10 \u03bcL, and the\n9\nglycine hydrochloride (betaine-D ) and choline-trimethyl-D oventemperaturewas50\u00baC.Thesampleruntimewas15min.\n9 9\nchloride were obtained from Isotec (Miamisburg, Ohio, The chromatographic separationwas performed ona Waters\nUSA), D -trimethylamine-N-oxide (TMAO), and D -carni- Aquity BEH amide 2.1\u00d7100 mm, 1.7 \u03bcm UPLC column.\n9 3\ntinewereobtainedfromCambridgeIsotopeLaboratories(An- myo-Inositol was monitored using selected ion monitoring\ndover, MA, USA), and N,N-dimethyl-D -glycinehydrochlo- (SIM) in negative ion mode at m/z=179.2 for myo-inositol,\n3\nrideand2-aminoethane-D -sulfonicacid(deuteratedtaurine) and m/z=185.2 for D -myo-inositol. The capillary voltage\n4 6\nwere obtained from CDN isotopes (Pointe-Claire, Quebec, wassetto2,500V,thecoronacurrentwassetto15\u03bcA,the\nCanada). Ammonium formate and formic acid were pur- drying gas was 12 L/min, the drying gas temperature was\nchased from Sigma-Aldrich (St Louis, MO, USA). HPLC 250\u00baC,andthevaporizingtemperaturewas400\u00baC.\ngrade acetonitrile was obtained from Mallinckrodt (Paris, Otherassaymeasurementsonbloodandurinewerecarried\nKY, USA), and methanol was obtained from Merck (Darm- outinaccreditedclinicallaboratories.\nstadt,Germany).\nAssayProcedures StatisticalAnalyses\nSamplesweremeasuredusingtandemmassspectrometry(LC- Statistical analyses wereperformed using SigmaPlot version\nMS/MS).Fiftymicrolitresofplasmaorurinewasextractedinto 11.2(SystatSoftwareInc),anddatawereplottedgraphically.\n1.0 mL of 10 % methanol, 90 % acetonitrile containing Thesignificanceofdifferencesbetweengroupswasassessed\n10 \u03bcmol/L of deuterated internal standard. Internal standards bythenon-parametricMann\u2013Whitneyranksumtest.Multiple\naddedincluded:D9-betaine,D9-choline,D3-dimethylglycine, regression models were calculated by calculating at least 12\nD3-carnitine,andD4-taurine.Plasmaandurinesampleswere BestSubsetregressionmodelsandcombiningtheconsistently\nanalysedforbetaine,glycerophosphorylcholine(GPC),taurine, significant predictors in explicit linear regression models;\nN,N-dimethylglycine(DMG), free choline,trimethylamine-N- excretionswerelog-transformedfortheseanalyses,sincethe\noxide (TMAO), carnitine, and acetylcarnitine (AC). An distributions of these data more closely approximated a log-\nABSciex (Mulgrave, VIC, Australia) API4000 triple quadru- normal distribution. Correlations were assessed using\npolemassspectrometerwasconnectedtoaShimadzuPromi- Spearman\u2019scorrelation.\nnence(Kyoto,Japan)HPLCwithabinarypumpsystem,and\nusedforanalysiswithaflowrateof300\u03bcL/min.Theinjection\nvolume was 10 \u03bcL. Samples were separated using a Cogent\n100 mm\u00d72.1 mm, 4 \u03bcm Diamond Hydride silica column\n(Microsolv Technologies, NJ, USA). The oven temperature Results\nwas 40\u00baC. Line A contained 10 mmol/L ammonium formate\nand10mmol/Lformicacidin50%distilledwaterand50% PropertiesofSamplePopulations\nacetonitrile.LineBcontained10mmol/Lammoniumformate,\n10mmol/Lformicacid,90%acetonitrileand10%water.The The participants treated with bezafibrate and the comparator\ngradientusedfortheanalysiswas:50%Agoingto100%A groupnotonfibratesdidnotdifferintheiranthropomorphic\nover8min.Anelectrosprayionsourcewasusedwithanion characteristics,nordidtheydifferinmostgeneralbiochemical\nsourcetemperatureof350\u00baC.Thedwelltimewas150ms. measures except for higher plasma total homocysteine con-\nTaurinewasseparatedisocraticallyusinganXBridgeam- centrations in the bezafibrate treated participants, and small\nidecolumn(100\u00d72.1mm,3.5\u03bcm,Waters,USA).Themobile differences in blood lipids (Table 2). Both groups had equal\nphase contained 20 % water and 80 % acetonitrile, the flow numbers of male and female participants. The participants\nratewasof0.3ml/min,theinjectionvolumewas10\u03bcL,and taking bezafibrate and the comparator group had similar\nthe oven temperature was 40\u00baC. Taurine was measured in (57\u201360%)proportionstakingconcurrentstatins,withvirtual-\nnegativeionmode. ly identical mean and median dosages (p>0.9); only one\nThemasstransitionsandinstrumentsettingsthatwereused participant (also taking a statin and bezafibrate) was being\nfordetectionareshowninTable1. treatedconcurrentlywithniacin.\n462 CardiovascDrugsTher(2014)28:459\u2013468\nTable1 Masstransitionsandin-\nstrumentsettingsformass Masstransition DP(eV) CE(eV) CXP(eV) Internalstandard\nspectrometry\nAnalytes:\nBetaine 118.2\u219259.0 56 27 4 D-Betaine\n9\nCholine 104.1\u219260.2 16 25 4 D-Choline\n9\nN,N-Dimethylglycine 104.1\u219258.1 51 21 4 D-Dimethylglycine\n3\nAcetylcarnitine 204.3\u219285.2 81 31 8 D-Carnitine\n3\nCarnitine 162.1\u219285.0 71 31 16 D-Carnitine\n3\nTrimethylamine-N-oxide 76.1\u219258.1 16 27 10 D-TMAO\n9\nGlycerophosphorylcholine 258.2\u2192104.0 66 23 8 D-Betaine\n9\nTaurine 124.1\u219280 \u221255 \u221230 \u221213 D-Taurine\n4\nInternalstandards:\nD-Betaine 127.2\u219268.0 61 27 4\n9\nD-Choline 113.2\u219269.0 61 27 2\n9\nD-N,N-Dimethylglycine 107.2\u219261.0 46 29 4\n3\nD-Carnitine 165.2\u219285.0 61 29 6\n3\nD-Trimethylamine-N- 85.2\u219266.0 91 29 2\nDPdecouplingpotential,CEcol- o9\nxide\nlisionenergy,CXPcollisioncell D-Taurine 128.1\u219280 \u221255 \u221230 \u221213\n4\nexitpotential\nDifferencesBetweenBezafibrateParticipants 6.6%inthecomparatorgroupnotonfibrates(p<0.001):ina\nandtheComparatorGroup healthypopulationthemeanclearanceis<1.5%[9].Fourof\nthe bezafibrate-treated subjects had fractional clearances of\nThemedianurinarybetaineexcretionintheparticipantstak- betaine>100%(highest187%).\ningbezafibratewas5-foldmorethaninthecomparatorgroup Dimethylglycineexcretionwasalsonine-foldhigherinthe\nnotonfibrates,p<0.001(Fig.1).Themedianexcretioninthe participants taking bezafibrate compared with the comparator\ncomparatorgroupnotonfibrates,27.8mmol/molecreatinine, groupnotonfibrates,p<0.001(Fig.1).Themedianfractional\nwas already 3.5-fold higher than in a population without clearance of dimethylglycine was 45 % in participants taking\ndiabetes [3, 5]. Nine (of 32) bezafibrate-treated participants bezafibrate, compared with 23 % in the comparator group\nwereexcretingmorethan200mmolebetainepermolecreat- (p<0.001); one of the bezafibrate-treated participants had an\ninine;onlyone(of64)controlparticipantswasexcretingthat excretion over 100 %. However, the excretions of some\nmuch. The median fractional clearance of betaine in the other osmolytes (taurine and myo-inositol, Fig. 1, and\nbezafibrate-treated participants was 43.5 %, compared with glycerophosphorylcholine,notshown)werenotsignificantly\nTable2 Characteristicsofthe\nstudygroups Median(interquartilerange)\nComparatorgroup Bezafibratetreated\nNumber 64 32\nAge(years) 61.5(54\u201367) 60.0(55\u201368)\nBMI 34.4(31.7\u201338.9) 34.9(33.7\u201340.2)\nTotalbodyfat(%) 41.3(35.5\u201348.9) 42.7(36.3\u201350.7)\nPlasmacreatinine(\u03bcmol/L) 76(63\u201386) 70(57\u201394)\nPlasmahomocysteine(\u03bcmol/L) 8.8(7.1\u201310.6) 11.5(8.6\u201314.2)a\nPlasmafolate(nmol/L) 18.5(12.4\u201328.4) 18.5(12.3\u201326.7)\nPlasmaB (pmol/L) 333(269\u2013411) 318(218\u2013449)\n12\naSignificantlydifferentfrom\nPlasmaHDLcholesterol(mmol/L) 1.07(0.97\u20131.25) 0.95(0.75\u20131.13)b\ncomparatorgroupnotonfibrates\n(p<0.001,Mann\u2013WhitneyRank PlasmaLDLcholesterol(mmol/L,est) 2.60(1.98\u20133.14) 3.00(2.41\u20133.51)b\nSumTest) Plasmatriacylglycerol(mmol/L) 1.65(1.36\u20132.17) 1.91(1.20\u20132.64)\nbSignificantly different, p<0.05. HemoglobinA (%) 7.4(7.0\u20138.6) 7.9(7.3\u20138.9)\n1c\nNo other differences are signifi- Urinaryalbumin(mg/L) 1.3(0.7\u20137.0) 1.8(0.8\u201316.5)\ncant(p>0.05)\nCardiovascDrugsTher(2014)28:459\u2013468 463\nFig.1 Urinaryexcretionsof\nbetaine(a),N,N-dimethylglycine A B\n(DMG,b),andtwoosmolytes 100\n(taurine,candmyo-inositold)in 100\nparticipantstakingbezafibrate\ncomparedwithageandsex\n10\nmatchedparticipantsnottakinga\nfibratedrug.Wherenop-valueis 10\nshownthedifferencewasnot\nsignificant(p>0.05) p<0.001 1 p<0.001\nNofibrate Bezafibrate Nofibrate Bezafibrate\nC\nD\n100 100\n10\n10\n1\nNofibrate Bezafibrate\nNofibrate Bezafibrate\ndifferentinthebezafibrate-treatedgroup.Neitherwastheexcre- Thefractionalclearanceofbetainewasinverselyrelatedto\ntion of the betaine precursor, choline. The median thefractionalclearanceofmyo-inositol;Spearman\u2019sr=\u22120.75\ntrimethylamine-N-oxide excretion was slightly higher in the (p<0.001) in the comparator group and \u22120.56 (p=0.002) in\nbezafibrate-treatedparticipants(102cf68mmol/molecreatinine, theparticipantstakingfibrates(Fig3b).Therewerenocorre-\np=0.032). Although carnitine excretion was not significantly lationsbetweenthefractionalclearancesoftaurineandeither\ndifferent in the two groups (median excretion 15.4 in treated betaineormyo-inositol.\nparticipants, cf 13.7 mmol/mole creatinine in the controls), Multipleregressionmodelsofpredictorsofbetaineexcretion\nacetylcarnitine excretion was lower in the treated participants werecalculated(withallexcretionslog-transformed)usingboth\n(1.6cf4.0mmol/moleinthecomparatorgroup:p<0.001). best-subset regression, followed by explicit multiple linear re-\nMedianplasmabetaineconcentrationswere16%lowerinthe gressionofthevariablesthatweremostconsistentlysignificant\nbezafibratetreatedparticipants(Fig.2:p=0.032),buttherewas in the best subset models. In the comparator group not on\nno significant difference in plasma dimethylglycine concentra- fibrates,thesamevariablesasinTable3weresignificantpredic-\ntions (Fig. 2). Plasma concentrations of choline, taurine and tors,withtheadditionofplasmaN,N-dimethylglycinewhichwas\nglycerophosphorylcholine were also not significantly different. consistentlysignificant(p<0.0001)withanegativecoefficient,\nBoththemedianplasmacarnitineandacetylcarnitineconcentra- that is, higher urinary betaine excretion was associated with\ntionswerehigherinthebezafibrateparticipants(Fig.2),byabout lower plasma dimethylglycine concentrations, as well as with\n26%(p<0.001)and32%(p=0.009)respectively.Themedian higherurinarydimethylglycineexcretion.Asimilarbutweaker\nplasmatrimethylamineN-oxideconcentrationwasalsohigherin association with plasma dimethylglycine was observed in the\nthetreatedparticipants(10.4cf6.0\u03bcmol/L,p=0.019). participantstakingbezafibrate,butthiswasonlysignificant(p=\n0.008)ifplasmacreatininewasalsoincludedinthemodel;inthe\nFactorsAssociatedwithBetaineExcretion bezafibrategroup(butnotthecomparatorgroup)plasmacreati-\nninewasasignificantpositivepredictorofbetaineexcretion(p=\nBetaineexcretionpositivelycorrelatedwithHbA andwith 0.030)inmultipleregressionmodels.\n1c,\ntheexcretionofseveralothermetabolites,inboththepartic-\nipantsreceivingbezafibrateand inthecomparatorgroupnot FactorsAssociatedwithPlasmaHomocysteine\nonfibrates(Table3).Theassociationsweresimilardespitethe Concentrations\nmuchhigherbetaineexcretioninthebezafibrategroup.Beta-\nineexcretioncorrelateswithboththeexcretionsofone-carbon Plasmamyo-inositolwastheonlyvariablemeasuredinthisstudy\nmetabolites associated with betaine (choline and N,N- thatcorrelatedstronglywithplasmahomocysteinemeasurements\ndimethylglycine), and with excretions of some other (Table4).Inparticulartherewasnostrongassociationbetween\nosmolytes (particularly myo-inositol, Fig. 3a) which are not betaineexcretionandplasmahomocysteine.However,inmulti-\nassociatedwithone-carbonmetabolism. ple regression models, both plasma and urine betaine and\n)eninitaerc\nelom/lomm(\nnoitercxe\neniateB\n)eninitaercelom/lomm(noitercxe\neniruaT\n)eninitaerc\nelom/lomm(\nnoitercxe\nGMD\n)eninitaerc\nelom/lomm(\nnoitercxe\nlotisonI-oym\n464 CardiovascDrugsTher(2014)28:459\u2013468\nFig.2 Plasmaconcentrationsof\nbetaine(a),N,N-dimethylglycine\n(DMG,b),carnitine(c)and\nhomocysteine(d)inparticipants\ntakingbezafibratecomparedwith\nageandsexmatchedparticipants\nnottakingafibratedrug.Where\nnop-valueisshownthedifference\nwasnotsignificant(p>0.05)\ndimethylglycine were found to be predictors of plasma homo- urinary excretion of dimethylglycine was negatively associated\ncysteine. An unexpected result was that in these models the with plasma homocysteine (p=0.001 in the comparator group,\n0.013inthebezafibrategroup),andsincebetaineexcretionand\nTable3 Factorsassociatedwithbetaineexcretion dimethylglycineexcretionstronglycorrelate(Table3)theposi-\ntiveassociationofbetaineexcretionwithplasmahomocysteine\nCorrelationofbetaineexcretionwith: Comp.group Bezafibrate\n(n=64) (n=32) wasmasked.Plasmadimethylglycinewaspositivelyassociated\nwithhomocysteineandplasmabetainenegativelyassociatedin\nBMI(kg/m2) \u22120.21 0.04 multipleregressionmodels.Parametersinthemultipleregression\n0.11 0.84 modelswerenotsignificantlydifferentbetweenthecomparator\nHemoglobinA 1c(%) 0.43 0.51 groupandthebezafibrategroup.\n<0.001 0.004 Itwassubsequentlyfoundthatplasmamyo-inositolwasthe\nCholineexcretion(mmol/mole 0.70 0.46 mostconsistentpredictorofplasmahomocysteineinmultiple\ncreatinine) <0.001 0.009 regressionmodelsusingthecomparatorgroupnotonfibrates,\nN,N-Dimethylglycineexcretion 0.78 0.8 moresothanplasmafolate,holo-transcobalaminorcreatinine;\n(mmol/molecr) <0.001 <0.001 the association was positive (p<0.001). Plasma inositol did\nTaurineexcretion(mmol/mole 0.21 0.03 not correlate with inositol excretion (r=\u22120.05, p=0.67). In\ncreatinine) 0.09 0.89 regressionmodelsthatincludedplasmainositolonlyplasma\nmyo-Inositolexcretion(mmol/mole 0.71 0.54 dimethylglycine was a significant positive predictor (p=\ncreatinine) <0.001 0.003 0.016), though the trends with betaine and dimethylglycine\nGlycerophosphorylcholineexcr. 0.52 0.58 excretionsandplasmabetainewereconsistentwiththeearlier\n(mmol/molecr) <0.001 <0.001 results(p~0.1).Thepatternwiththebezafibrate-treatedpar-\nPlasmabetaine(\u03bcmol/L) 0.01 \u22120.27 ticipantsappeareddifferent:plasmamyo-inositoldidnotenter\n0.96 0.15\nthemodelsasasignificantpredictor(p>=0.19)butgiventhe\nPlasmacreatinine(\u03bcmol/L) \u22120.003 0.18 small numbers this negativeresultmustbetreatedwithcau-\n0.98 0.32 tion(thecoefficientswerenotsignificantlydifferent).\nPlasmamyo-inositol(\u03bcmol/L) \u22120.12 \u22120.11\n0.36 0.56 FactorsAssociatedwiththeEstimatedGlomerularFiltration\nPlasmahomocysteine(\u03bcmol/L) 0.02 \u22120.14 Rate\n0.87 0.48\nInthecomparatorgroup,theonlyfactorsthatwereconsistent-\nSpearman correlation coefficients given with significance underneath.\nlyassociatedwiththeeGFRinregressionmodelswereplasma\nSignificant(p<0.05)correlationsshowninbold.\u201cBezafibrate\u201ddenotes\nmyo-inositol(negativeassociation)andtheexcretionofN,N-\nstudyparticipantstreatedwithbezafibrate;Comparatorgroupareageand\nsexmatchedparticipantsfromthesamestudy dimethylglycine (positive association), although in a simple\nCardiovascDrugsTher(2014)28:459\u2013468 465\nFig.3 Comparisonofbetaineexcretionandmyo-inositolexcretion.Data takingafibrate,thecorrespondingcorrelationforthosetakingafibrate\nfrom study participants taking bezafibratemarked with open triangles, wasr=+0.54(p=0.003).bFractionalclearances;Spearman\u2019scorrelation\nmatched participants not taking a fibrate marked with filled circles. a givenfortheparticipantsnottakingafibrate,thecorrespondingcorrela-\nExcretion data; Spearman\u2019s correlation given for the participants not tionforthosetakingafibratewasr=\u22120.56(p=0.002)\nmultipleregressionmodelforeGFRwithjustthesetwovar- excretion) was only p=0.053 compared with p<0.001 for\niables (r2=0.26) the significance of log(dimethylglycine plasma inositol. Plasma homocysteine only entered models\nasasignificantfactorifplasmainositolwereleftout.Betaine\nandtrimethylamineN-oxide,plasmaorurine,wereinnocase\nTable4 Factorsassociatedwithplasmahomocysteine\nsignificantcontributorstothemodels.Apossiblecontribution\nCorrelationofplasmahomocysteine Comp.group Bezafibrate fromplasmataurineneedsfurtherinvestigation:inmorethan\nwith: (n=64) (n=32) adozenmodelstherewasatrend(withpositivecoefficients),\n0.05<p<0.1.\nBMI(kg/m2) 0.09 \u22120.06\nThepatternwaspossiblynodifferentinthegrouptreated\n0.53 0.74\nwithbezafibrate,butwiththesmallernumberonlytheplasma\nHemoglobinA 1c(%) 0.1 0.56 myo-inositol (negative coefficient) could be demonstrated to\n0.43 0.002 beasignificantcontributor(p=0.042).\nBetaineexcretion(mmol/mole \u22120.12 \u22120.14\ncreatinine) 0.34 0.48\nCholineexcretion(mmol/mole \u22120.23 \u22120.07\ncreatinine) 0.064 0.73 Discussion\nN,N-Dimethylglycineexcretion \u22120.11 \u22120.32\n(mmol/molecr) 0.39 0.086 Betaine excretion is abnormally elevated (above the 97.5\nTaurineexcretion(mmol/mole \u22120.16 \u22120.11 percentile for a healthy adult population) in about one third\ncreatinine) 0.22 0.57 ofsubjectswithdiabetes[3,5],andthisisthecaseinoverhalf\nmyo-Inositolexcretion(mmol/mole \u22120.13 0.16 of the DEWL study participants. Betaine excretion is also\ncreatinine) 0.33 0.4 elevatedinpatientstreatedwithbezafibrate[9,29].Theresults\nPlasmabetaine(\u03bcmol/L) 0.14 \u22120.13 reported here suggest that these effects are cumulative.\n0.27 0.48 Fenofibrate increases betaine excretion by healthy subjects\nPlasmaN,N-dimethylglycine 0.31 0.23 by factors related to their baseline excretion [15], and the\n(\u03bcmol/L)\n0.013 0.21 results hereare consistentwiththisbeing true ofbezafibrate\nPlasmamyo-Inositol(\u03bcmol/L) 0.51 0.46 aswell,makingthisaclasseffect.Asaresult,somepatients\n<0.001 0.01 withtype2diabeteswhoaretreatedwithafibratemayexcrete\nPlasmacreatinine(\u03bcmol/L) 0.3 0.43 more than the normal dietary intake of betaine: the median\n0.016 0.018 intake is about 100\u2013300 mg/day in different populations\n[30\u201333],thatis, about 1\u20132 mmoles betaine/day, and about a\nSpearman correlation coefficients given with significance underneath.\nthirdoftheparticipantsinthisstudywhowerealsoreceiving\nSignificant(p<0.05)correlationsshowninbold.\u201cBezafibrate\u201ddenotes\nbezafibrate were probably excreting at least this quantity of\nstudyparticipantstreatedwithbezafibrate;Comparatorgroupareageand\nsexmatchedparticipantsfromthesamestudy betaine.Thusitislikelythatmanypatientswithdiabeteswho\n466 CardiovascDrugsTher(2014)28:459\u2013468\narebeingtreatedwithfibratesaredependentonmitochondrial Although the disturbing effects of diabetes and of fibrates\ncholine oxidation to maintainthe reservesofbetaine needed appear to have sufficiently different selectivities to suggest\nfor cellular osmoregulation and for one-carbon metabolism different mechanisms, in both cases there is a fairly specific\n[3].Wehaveelsewhereprovidedevidencethatadisruptionin effect on betaine efflux. One possible driver would be an\nthesupplyoftissuebetainemayincreasecardiovascularrisk, overproduction of another osmolyte such as sorbitol or myo-\nespecially in type 2 diabetes [1], and this effect is likely to inositol;sorbitolwasnotmeasuredinthisstudy,butitsreported\ncompromiserisk-reductionbybezafibratetherapy. increasedexcretionindiabetes[9,34]isquantitativelylessthan\nThis observational study provides limited insight into the thatofbetaine.Althoughmyo-inositolexcretionisincreasedin\nmechanismsbywhichbetaineexcretioniselevatedindiabetes diabetesnearlyasmuchasbetaineexcretion[34],noincreaseis\nand on treatment with fibrate. Clearly betaine excretion is apparentonfibratetreatment[15],andthisisconsistentwiththe\nassociatedwithglycemiccontrol(indicatedbyHbA measure- resultsofthisstudy.However,theinverserelationshipbetween\n1c\nments),asothershaveobserved[5].Previouslywehavereport- the fractional clearances of myo-inositol and betaine (Fig. 3b)\ned that sorbitol excretion correlates with betaine excretion in leavesopenthepossibilityofsomecompensatoryprocess,with\ndiabetes[9],butnotinotherconditions.Hereweshowthatthe one osmolyte replacing another, but even if true fibrate treat-\nexcretions of two other osmolytes (glycerophosphorylcholine mentdoesnotaltertherelationship,since(Fig.3)thetrendsin\nand especially myo-inositol) also correlate with betaine excre- the relationship between betaine and inositol excretions are\ntionindiabetes:butsoalsodotheexcretionsofsomeimportant simply displaced by the increased betaine excretion. Alterna-\none-carbonmetabolites(cholineandN,N-dimethylglycine)that tively, the relationship could result from the fact that while\nare not directly involved in osmoregulation, associations that urinaryexcretionsofthetwoosmolytesarepositivelycorrelat-\nhave also been shown in a larger study [5]. Bezafibrate treat- ed,plasmabetaineispositivelyassociated,butplasmainositolis\nmentappearstoaltertheserelationships,butthedifferencesare negativelyassociated,withrenalfunction.Thiswouldneedto\nnotstatisticallysignificantanddirectexperimentalevidenceis beclarifiedbyadifferentkindofstudytothatreportedhere.\nneeded to confirm that the mechanisms for the increases in Historically,elevatedplasmaconcentrationsofthebetaine\ndiabetes and fibrate treatment are different. A strong indicator analog, trimethylamine N-oxide, have been associated with\nisthatmyo-inositolexcretion,whichisincreasedmorethansix- renal failure [26, 27]. Recently, this metabolite has been\nfold in diabetes [34], was not increased further by bezafibrate reportedtobeastrongriskmarkerforcardiovasculardisease\ntreatment.However,thecomplexityoftheassociationsdoesnot [22\u201325].Ithas alsobeenusedasabiomarkerofdietaryfish\nsupportourearliersuggestion[35]thatthelossofbetaineisa consumption in seals [40], which we have confirmed in a\ndirect cause of the elevation in plasma homocysteine seen in humanpopulation(McEntyre,unpublisheddata),butelevated\nfibratetreatment.Itismorelikelythatthesearemultipleindirect plasmaconcentrationscanalsoarisefromtheconsumptionof\neffects of the action of the fibrates, which is believed to be foodscontainingcholine[22]orcarnitine[23].Weobserved\nmediatedthroughtheactivationofthenuclearreceptorPerox- slightly higher plasma concentrations in the fibrate treated\nisome Proliferator Activated Receptor-\u03b1, PPAR-\u03b1 [36]. It has participants in this study and the urinary excretion was also\nbeenshowninaratmodel[37]thatPPAR-\u03b1activationaffects slightlyelevated:however,inhealthyadultsurinaryexcretion\namino acid metabolism, including down-regulation of the mi- of trimethylamine N-oxide was not affected by fenofibrate\ntochondrial pathway for further demethylation of N,N- treatment [15]. Resolving the reason for this difference will\ndimethylglycine,andatissueaccumulationofdimethylglycine needadifferentkindofstudy.Thedifferencemayrelatetothe\nmightbeexpectedtoinhibitthedemethylationofbetaine.This underlyingconditionsthatthefibratewasprescribedtotreat,\nisbecausebetainemetabolism,andbetaine-mediatedcontrolof and a difference in renal function would also be an obvious\nhomocysteine,ismediatedthroughtheosmoregulatedenzyme area to investigate, though our data on factors affecting the\nbetaine-homocysteinemethyltranferase[3,38]whichisstrong- eGFRdoesnotshowtrimethylamineN-oxideasasignificant\nlyfeedbackinhibitedbythereactionproduct,dimethylglycine. factor.\nHowever,giventhaturinarybetainelossisquantitativelymuch An incidental finding was the association in this cohort\ngreaterthanthelossoftheothermetabolites,wesuspectthata between the important osmolyte myo-inositol and homocys-\nmore likely place to look would be the control of metabolite teine;thismaynotbedirectlyrelevanttobetainemetabolism\neffluxfromrenalepithelialcells,wherehighconcentrationsof but it may be a consequence of the linkage between one\nbetaine are accumulated. Most betaine in normal urine arises carbon metabolism and osmoregulation. Inositol production\nfromeffluxfromthesecellsratherthanfromthecirculation.The may increase when the supply of the osmolyte betaine is\nhighfractionalclearancesinsomeparticipants,includingsome compromised,aconditionassociatedwithelevatedhomocys-\nover100%,strengthenthesuspicionthatthisiswheretoseek teine [3]. Whether fibrate therapy has any effect on inositol\nmechanisms.Littleisknownaboutthecontrolofbetaineefflux, metabolismwouldrequireadifferentkindofstudythanthat\nbutinlivercellsitisbothosmoregulatedandunderhormonal carried out here. Carnitine and acetylcarnitine metabolism\ncontrol,withthecontrollinghormonesincludingglucagon[39]. differ in the fibrate treated subjects and the controls, but\nCardiovascDrugsTher(2014)28:459\u2013468 467\nalthoughcarnitineisabetaine,andsharessomebetainetrans- 11. WierzbickiAS.Fibrates:noACCORDontheiruseinthetreatment\nofdyslipidaemia.CurrOpinLipidol.2010;21:352\u20138.\nport systems, its metabolic role in fatty acid metabolism is\n12. Hamilton-CraigI,KostnerKM,WoodhouseS,ColquhounD.Useof\nprobably more relevant here. The differences may either re-\nfibratesinclinicalpractice:Queenslandlipidgroupconsensusrec-\nflect the effect of the fibrate on lipid metabolism, or charac- ommendations.IntJEvidBasedHealthc.2012;10:181\u201390.\nteristics in the study subgroups thatare related to the reason 13. BerglundL,BrunzellJD,GoldbergAC,GoldbergIJ,SacksF,Murad\nMH, et al. Evaluation and treatment of hypertriglyceridemia: an\nforprescribingbezafibrate.\nendocrine society clinical practice guideline. J Clin Endocrinol\nRegardlessofthemechanisms,thescaleofurinarybetaine Metab.2012;97:2969\u201389.\nlosses reported here suggest that the possibility that patients 14. JackeviciusCA,TuJV,RossJS,KoDT,CarreonD,KrumholzHM.\ntreated with fibrates, especially if they have diabetes, would UseoffibratesintheUnitedStatesandCanada.JAMA.2011;305:\n1217\u201324.\nbenefit from concurrent dietary betaine supplementation\n15. LeverM,McEntyreCJ,GeorgePM,SlowS,ChambersST,Foucher\nshould be investigated. Betaine supplementation is inexpen-\nC.Fenofibratecauseselevationofbetaineexcretionbutnotexcretion\nsiveandsafe[41]andmaybesynergisticwithfibratetherapy ofotherosmolytesbyhealthyadults.JClinLipidol2014.\n[42]inreducingcardiovascularrisk.Prospectivestudiesofa 16. KrebsJ,ElleyC,Parry-StrongA,LuntH,DruryPL,BellDA,etal.\nThe Diabetes Excess Weight Loss (DEWL) trial: a randomised\ncombinationtherapywouldbejustified.\ncontrolledtrialofhigh-proteinversushigh-carbohydratedietsover\n2yearsintype2diabetes.Diabetologia.2012;55:905\u201314.\n17. Fruchart J-C, Sacks FM, Hermans MP, et al. The residual risk\nAcknowledgments The DEWL trial was funded by the Health Re-\nreduction initiative: a call to action to reduce residual vascular\nsearch Council of New Zealand (06/337). Other work has been made\nrisk in dyslipidaemic patients. Diab Vasc Dis Res. 2008;5:\npossiblewithsupportfromtheHeartFoundationofNewZealand,the 319\u201335.\nMaurice & Phyllis Paykel Trust, and equipment funded by Lotteries 18. Reiner \u017d. Combined therapy in the treatment of dyslipidemia.\nHealth NZ. None of the sponsors had any role in the conduct of the FundamClinPharmacol.2010;24:19\u201328.\nresearchoritsinterpretation.\n19. BarterPJ,RyeK-A.Istherearoleforfibratesinthemanagementof\ndyslipidemiainthemetabolicsyndrome?ArteriosclerThrombVasc\nBiol.2008;28:39\u201346.\n20. Hottelart C, El Esper N, Archard JM, Pruna A, Fournier A.\nReferences Fenofibrateincreasesbloodcreatinine,butdiesnotchangetheglo-\nmerular filtration rate in patients with mild renal insufficiency.\nNephrologie.1999;20:41\u20134.\n1. LeverM,GeorgePM,ElmslieJL,AtkinsonW,SlowS,Molyneux 21. FruchartJ-C,DavignonJ,HermansMP,etal.Fortheresidualrisk\nSL,etal.Betaineandsecondary eventsinan acutecoronarysyn- reductioninitiative(R3i).Residualmacrovascularriskin2013:what\ndromecohort.PLoSOne.2012;7(5):e37883. havewelearned?CardiovascDiabetol.2014;13:26.\n2. Svingen GFT, Ueland PM, Pedersen EKR, Schartum-Hansen H, 22. WangZ,KlipfellE,BennettBJ,KoethR,LevisonBS,DuGarB,\nSeifert R, Ebbing M, et al. Plasma dimethylglycine and risk of etal.Gutflorametabolismofphosphatidylcholinepromotescardio-\nincident acute myocardial infarction in patients with stable angina vasculardisease.Nature.2011;472:57\u201363.\npectoris.ArteriosclerThrombVascBiol.2013;33:2041\u20138. 23. KoethRA,WangZ,LevisonBS,BuffaJA,OrgE,SheehyBT,etal.\n3. LeverM,SlowS.Theclinicalsignificanceofbetaine,anosmolyte Intestinalmicrobiotametabolismofl-carnitine,anutrientinredmeat,\nwithakeyroleinmethylgroupmetabolism.ClinBiochem.2010;43: promotesatherosclerosis.NatMed.2013;19:576\u201385.\n732\u201344. 24. TangWH,WangZ,LevisonBS,KoethRA,BrittEB,FuX,etal.\n4. LeverM,GeorgePM,SlowS,ElmslieJL,ScottRS,RichardsAM, Intestinalmicrobialmetabolismofphosphatidylcholineandcardio-\netal.Fibratesmaycauseanabnormalurinarybetainelosswhichis vascularrisk.NEnglJMed.2013;368:1575\u201384.\nassociated with elevations in plasma homocysteine. Cardiovasc 25. Wang Z, Tang HW, Buffa JA, Fu X, Britt EB, Koeth RA, et al.\nDrugsTher.2009;23:395\u201340. Prognostic value of choline and betaine depends on intestinal\n5. Schartum-HansenH,UelandPM,PedersenER,MeyerK,EbbingM, microbiota-generatedmetabolitetrimethylamine-N-oxide.EurHeart\nOvindB,etal.Assessmentofurinarybetaineasamarkerofdiabetes J.2014;35:904\u201310.\nmellitusincardiovascularpatients.PLoSOne.2013;8:e469454. 26. BellJD,LeeJA,LeeHA,SadlerPJ,Wilkie,WoodhamRH.Nuclear\n6. Lever M, George PM, Dellow WJ, Scott RS, Chambers ST. magneticresonancestudiesofbloodplasmaandurinefromsubjects\nHomocysteine,glycinebetaine,andN,N-dimethylglycineinpatients withchronicrenalfailure:identificationoftrimethylamine-N-oxide.\nattendingalipidclinic.Metabolism.2005;54:1\u201314. BiochimBiophysActa.1991;1096:101\u20137.\n7. LeverM,GeorgePM,AtkinsonW,ElmslieJL,SlowS,Molyneux 27. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM.\nSL,etal.Thecontrastingrelationshipsbetweenbetaineandhomo- Accumulation of trimethylamine and trimethylamine-N-oxide in\ncysteineintwoclinicalcohortsareassociatedwithplasmalipidsand end-stagerenaldiseasepatientsundergoinghaemodialysis.Nephrol\ndrugtreatments.PLoSOne.2012;7:e32460. DialTransplant.2006;21:1300\u20134.\n8. Lever M, Slow S, George PM, Chambers ST. Betaine excretion 28. McGregor DO, Dellow WJ, Lever M, George PM, Robson RA,\ncorrelateswithplasmahomocysteinewhenplasmalipidsareelevat- ChambersST.Dimethylglycineaccumulatesinuremiaandpredicts\ned.ClinBiochem.2012;45:154\u20136. elevatedplasmahomocysteineconcentrations.KidneyInt.2001;59:\n9. Lever M, Sizeland PC, Bason LM, Hayman CM, Robson RA, 2267\u201372.\nChambersST.Abnormalglycinebetainecontentofthebloodand 29. LeverM,GeorgePM,AtkinsonW,MolyneuxSL,ElmslieJL,Slow\nurineofdiabeticandrenalpatients.ClinChimActa.1994;230:69\u2013 S,etal.Plasmalipidsandbetainearerelatedinanacutecoronary\n79. syndromecohort.PLoSOne.2011;6:e21666.\n10. Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S. 30. SlowS,DonnaggioM,CresseyPJ,LeverM,GeorgePM,Chambers\nAntidiabeticactionofbezafibrateinalargeobservationaldatabase. ST.ThebetainecontentofNewZealandfoodsandestimatedintake\nDiabetesCare.2009;32:547\u201351. intheNewZealandDiet.JFoodCompAnal.2005;18:473\u20135.\n468 CardiovascDrugsTher(2014)28:459\u2013468\n31. ChiuveSE,GiovannucciEL,HankinsonSE,ZeiselSH,Dougherty 37. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR,\nLW,WillettWC,etal.Theassociationbetweenbetaineandcholine OakesND.Beyondlipids,pharmacologicalPPAR-alphaactivation\nintakesandtheplasmaconcentrationsofhomocysteineinwomen. hasimportanteffectsonaminoacidmetabolismasstudiedintherat.\nAmJClinNutr.2007;86:1073\u201381. AmJPhysiolEndocrinolMetab.2007;292:E1157\u20131165.\n32. Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, 38. HoffmannL,BrauersG,GehrmannT,H\u00e4ussingerD,MayatepekE,\nStefanadis C. Dietary choline and betaine intakes in relation to SchliessF,etal.Osmoticregulationofhepaticbetainemetabolism.\nconcentrations of inflammatory markers in healthy adults: the AmJPhysiolGastrointestLiverPhysiol.2013;304:G835\u201346.\nATTICAstudy.AmJClinNutr.2008;87:424\u201330. 39. WettsteinM,Peters-RegehrT,KubitzR,FischerR,HolneicherC,\n33. YonemoriKM,LimU,KogaKR,WilkensLR,AuD,CarolJ,etal. M\u00f6nnighoffI,etal.Releaseofosmolytesinducedbyphagocytosis\nDietary choline and betaine intakes vary in an adult multiethnic andhormonesinratliver.AmJPhysiolGastrointestLiverPhysiol.\npopulation.JNutr.2013;143:894\u20139. 2000;278:G227\u201333.\n34. YoshiiH,UchinoH,OhmuraC,WatanabeK,TanakaY,Kawamori 40. EisertR,OftedalOT,LeverM,RamdohrS,BreierBH,BarrellGK.\nR.Clinicalusefulnessofmeasuringurinarypolyolexcretionbygas- Detectionoffoodintakeinamarinemammalusingmarineosmolytes\nchromatography:mass-spectrometry in type 2 diabetes to assess and their analogues as dietary biomarkers. Mar Ecol Prog Ser.\npolyolpathwayactivity.DiabetesResClinPract.2001;51:115\u201323. 2005;300:213\u201328.\n35. LeverM,GeorgePM,AtkinsonW,ElmslieJL,SlowS,Molyneux 41. EuropeanFoodSafetyAuthority.ScientificOpiniononthesubstan-\nSL,etal.Thecontrastingrelationshipsbetweenbetaineandhomo- tiationofhealthclaimsrelatedtobetaineandcontributiontonormal\ncysteineintwoclinicalcohortsareassociatedwithplasmalipidsand homocysteine metabolism (ID 4325) pursuant to Article 13(1) of\ndrugtreatments.PLoSOne.2012;7(3):e32460. Regulation(EC)No1924/2006.EFSAJ.2011;9(4):2052.\n36. BrownJD,PlutzkyJ.Peroxisomeproliferator-activatedreceptorsas 42. LeverM,GeorgePM,SlowS,ElmslieJL,ShandBI,ScottRS,etal.\ntranscriptional nodal points and therapeutic targets. Circulation. Fibratesplusbetaine:awinningcombination?NZMedJ.2010;123:\n2007;115:518\u201333. 74\u20138.",
  "source": "sci-hub",
  "retrieved_at": "2025-01-05T18:51:12Z"
}